Table 1.

Synopsis of important clinical trials that specifically addressed T-PLL

Summary of most relevant clinical studies on chemo-/immunotherapy in T-PLL
Regime	Study design	Treatment status	n	ORR	CR	PR	PFS	OS	Reference
				[%]	[%]	[%]	[mo]	[mo]
Pentostatin	Single center, retrospective	Pretreated	56	45	9	36	6	9	[9]
Alemtuzumab, iv	Single center, retrospective	Pretreated	15	73	60	13	6	8	[34]
Alemtuzumab, iv	Multicenter, prospective	Pretreated	39	76	60	16	7	10	[33]
Alemtuzumab, iv	Multicenter, retrospective	Untreated	4	75	75	0	5	8.7	[30]
		Pretreated	72	50	37.5	12.5	4.5	7.5
Pentostatin + alemtuzumab, iv	Single center, prospective	Pretreated	13	69	62	8	7.8	10.2	[39]
Alemtuzumab, iv	Single center, prospective	Untreated	32	91	81	10	12	48	[10]
		Pretreated	45	74	60	14	12	48
Alemtuzumab, sc		Untreated	9	33	33	0	12	48
FMC + alemtuzumab, iv	Multicenter, prospective	Untreated	16	92	48	44	11.5	17.1	[5]
		Pretreated	9
Bendamustine	Multicenter, retrospective	Untreated	6	55.3	20	33.3	5	8.7	[24]
		Pretreated	9
Alemtuzumab, iv	Single center, retrospective	Untreated	13	n.a.	n.a.	n.a.	n.a.	40.5	[32]
Alemtuzumab, sc	Single center, retrospective	Pretreated	5	n.a.	n.a.	n.a.	n.a.	13.7	[32]
Alemtuzumab, iv + cladribine +/− HDAC inhibition	Single center, retrospective	Untreated	4	100	75	25	6.3	14.8	[52]
		Pretreated	4	100	100	0	11.35	23.7
Alemtuzumab, iv	Single center, retrospective	Untreated	42	81	61	20	11	15	[31•]
		Pretreated	15	46	46	0	3	15
Alemtuzumab, iv + pentostatin		Untreated	13	82	73	9	4.3	10.4
		Pretreated	5	75	50	25	2.6	2.6
FMC + alemtuzumab, sc	Multicenter, prospective	Untreated	13	68.7	32.1	36.6	7.5	11.5	[26•]
		Pretreated	5

iv intravenous, sc subcutaneous, FMC fludarabine, mitoxantrone, cyclophosphamide, HDAC histone deacetylase